Last updated: February 19, 2026
This report analyzes the supplier landscape for tafluprost, an prostaglandin analog used to treat glaucoma and ocular hypertension. Key suppliers of tafluprost active pharmaceutical ingredient (API) and finished drug product are identified, with a focus on regulatory status, production capacity, and geographical distribution. The analysis highlights significant players in both the generic and branded markets, as well as their roles in global supply chains.
Who are the Primary API Suppliers for Tafluprost?
The supply of tafluprost API is concentrated among a limited number of manufacturers, primarily in Asia. These suppliers are critical for both generic manufacturers and branded product formulators.
- Sagent Pharmaceuticals Inc.: Sagent, a subsidiary of Nichi-Iko Pharmaceutical, supplies tafluprost ophthalmic solution in the U.S. market. Their U.S. FDA approval for tafluprost signifies established manufacturing and quality control processes.
- Samil Pharmaceutical Co. Ltd.: Based in South Korea, Samil Pharmaceutical is a significant API manufacturer. They hold patents related to tafluprost synthesis and have been a supplier for various pharmaceutical companies globally. Samil's facility in Ansan, Gyeonggi-do, is FDA-inspected.
- Novelis Pharma Private Limited: This India-based company is an API manufacturer with capabilities in prostaglandin synthesis. Novelis supplies tafluprost API to formulators in regulated and semi-regulated markets.
- Other Manufacturers: Several other API manufacturers, particularly in India and China, produce tafluprost. These often serve as secondary suppliers or provide raw materials for primary API synthesis. Specific company names are not consistently disclosed due to proprietary supply agreements.
What are the Key Finished Drug Product Manufacturers and Marketers?
Tafluprost is marketed both as a branded product and as a generic alternative. The manufacturers and marketers vary by region and regulatory approval.
- Santen Pharmaceutical Co., Ltd.: Santen is the originator of tafluprost. Their branded product, Saflutan® (tafluprost ophthalmic solution 0.0015%), is marketed in Japan and Europe. Santen maintains significant control over its supply chain, from API sourcing to final product distribution. Saflutan® received marketing authorization in Japan in 2009 and in Europe in 2010.
- Merck & Co., Inc. (MSD): MSD, through its subsidiary Alcon, co-developed and markets tafluprost. The product, Lumigan® (bimatoprost) and Taflotan® (tafluprost) are distinct but compete in the same therapeutic class. MSD/Alcon's role is primarily in marketing and distribution, with API and drug product manufacturing often outsourced to contract manufacturing organizations (CMOs) or specific API suppliers.
- Generic Manufacturers: Numerous generic pharmaceutical companies have obtained approvals for tafluprost ophthalmic solution in various markets. These companies rely on third-party API suppliers.
- Teva Pharmaceutical Industries Ltd.: Teva offers a generic version of tafluprost in markets including the United States. Their generic tafluprost ophthalmic solution 0.0015% was approved by the FDA.
- Akorn, Inc.: Akorn has marketed generic tafluprost ophthalmic solution in the U.S.
- Bausch Health Companies Inc.: Bausch Health offers generic tafluprost ophthalmic solution.
- Eyegate Pharmaceuticals, Inc.: While not a direct manufacturer, Eyegate focuses on drug delivery systems that could potentially be used with tafluprost, impacting future market dynamics.
- Sun Pharmaceutical Industries Ltd.: Sun Pharma is a major generic manufacturer with a broad ophthalmic portfolio and is a potential supplier or marketer of generic tafluprost.
What is the Regulatory Landscape for Tafluprost Suppliers?
Regulatory compliance is paramount for tafluprost suppliers. Agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) set stringent requirements for API and finished product manufacturing.
- FDA (United States):
- API DMFs (Drug Master Files): API manufacturers must file Drug Master Files with the FDA, providing detailed information on the manufacturing process, quality control, and facility.
- cGMP Compliance: All manufacturing facilities, both for API and finished products, must adhere to current Good Manufacturing Practices (cGMP). FDA inspections verify compliance.
- ANDA Approvals: Generic drug companies seek Abbreviated New Drug Applications (ANDAs) for tafluprost, which include references to approved API DMFs.
- EMA (Europe):
- CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia): API manufacturers can obtain a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM), which attests to compliance with European Pharmacopoeia standards.
- GMP Compliance: Facilities must be certified for GMP compliance by national competent authorities within the EU.
- PMDA (Japan):
- Accreditation and Inspections: API and finished product manufacturers supplying to Japan undergo rigorous review and inspection by the PMDA.
- Geographic Concentration of Audits: Regulatory inspections for tafluprost suppliers are frequently conducted in India and China due to the concentration of API manufacturing in these regions.
What are the Key Manufacturing Technologies and Patents Affecting Tafluprost Supply?
The synthesis of tafluprost involves complex chemical processes, and patents play a significant role in market exclusivity and generic entry.
- Chiral Synthesis: Tafluprost is a chiral molecule, requiring stereoselective synthesis to produce the active (S)-enantiomer. This often involves asymmetric synthesis or chiral resolution techniques.
- Key Synthetic Intermediates: Patents often cover specific intermediates used in the multi-step synthesis of tafluprost. For example, patents related to the synthesis of the prostaglandin backbone are crucial.
- Process Patents: Innovations in reaction conditions, catalysts, purification methods, and yield optimization are often protected by process patents.
- Formulation Patents: Patents may also cover specific ophthalmic formulations, such as preservative-free solutions or specific excipient combinations that enhance stability or delivery.
- Patent Expirations: The expiration of key patents held by Santen Pharmaceutical has opened the door for generic competition, increasing the demand for tafluprost API from multiple sources.
- Original U.S. patent for tafluprost (e.g., related to its discovery and composition of matter) is likely expired or nearing expiration in major markets.
- The expiration dates of secondary process and formulation patents vary and dictate the timing of generic market entry and the types of products that can be launched.
What is the Global Market Demand and Production Capacity for Tafluprost?
Global demand for tafluprost is driven by the increasing prevalence of glaucoma and ocular hypertension, particularly in aging populations. Production capacity is generally considered sufficient, with potential for expansion by key API manufacturers.
- Glaucoma Incidence: Glaucoma is a leading cause of irreversible blindness worldwide. The World Health Organization estimates that 4.5 million people are blind due to glaucoma [1].
- Market Growth: The global ophthalmic drugs market is projected to grow, with prostaglandin analogs like tafluprost being a significant segment.
- API Production Capacity:
- Major API manufacturers in India and South Korea have established production lines for prostaglandin analogs, including tafluprost.
- Annual production capacity for tafluprost API is estimated to be in the metric tons range, sufficient to meet global demand for both branded and generic products.
- Scalability: Key API suppliers possess the technical expertise and infrastructure to scale up production in response to market demand or supply chain disruptions.
- Finished Product Capacity:
- Finished product manufacturing facilities, often operated by CMOs or the generic companies themselves, are also capable of meeting demand.
- Sterile ophthalmic filling lines are required, necessitating specialized cleanroom environments and aseptic processing capabilities.
Key Takeaways
- Santen Pharmaceutical is the originator and primary marketer of branded tafluprost (Saflutan®).
- Generic tafluprost is supplied by multiple companies, including Teva, Akorn, and Bausch Health, relying on API from manufacturers such as Samil Pharmaceutical and Novelis Pharma.
- Regulatory compliance, particularly cGMP and DMF filings with agencies like the FDA and EMA, is critical for all tafluprost suppliers.
- Tafluprost synthesis requires specialized chiral chemistry, and process patents influence market exclusivity.
- Global demand is robust due to the prevalence of glaucoma, and production capacity for both API and finished product is generally adequate.
Frequently Asked Questions
How do FDA inspections impact tafluprost API suppliers?
FDA inspections verify that tafluprost API manufacturers adhere to current Good Manufacturing Practices (cGMP). Failure to pass these inspections can result in import alerts, product recalls, and an inability to supply to the U.S. market, directly impacting commercial viability and market access.
What is the typical lead time for sourcing tafluprost API from Asian manufacturers?
Lead times for sourcing tafluprost API from manufacturers in India and China can range from 12 to 20 weeks, depending on existing inventory levels, production schedules, and the volume of the order. Custom synthesis or large-volume orders may require longer lead times.
Are there any known single-source dependencies for critical raw materials in tafluprost synthesis?
While tafluprost synthesis involves multiple steps and intermediates, there are generally no widely disclosed single-source dependencies for critical raw materials that would pose an immediate systemic risk. However, specific proprietary synthetic routes employed by individual manufacturers may rely on unique starting materials or catalysts.
What is the typical shelf life of tafluprost API?
The typical shelf life of tafluprost API, when stored under recommended conditions (e.g., cool, dry, protected from light), is generally between two to three years. Manufacturers provide specific Certificates of Analysis detailing expiry dates and recommended storage conditions.
How do patent expirations for tafluprost influence supplier selection for generic companies?
Patent expirations directly enable generic companies to enter the market. This increases the demand for tafluprost API and drives competition among API suppliers, potentially leading to price negotiations and a broader supplier base. Generic companies often qualify multiple API suppliers before and after patent expiry to ensure supply chain resilience.
Citations
[1] World Health Organization. (n.d.). Blindness and vision impairment. Retrieved from https://www.who.int/news-room/fact-sheets/detail/blindness-and-vision-impairment
